



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

4<sup>th</sup> August 2025

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir(s),

**Sub: Clarification on news item appearing in <https://www.moneycontrol.com>**

This is in reference to the communications dated August 1, 2025 received from National Stock Exchange of India Limited, bearing reference number: NSE/CM/Surveillance/15703, and from BSE Limited, bearing reference number: L/SURV/ONL/RV/AJ/ (2025-2026)/ 54, seeking clarification regarding the news article published on <https://www.moneycontrol.com> on August 1, 2025, titled '*Trump Tariff News Live: GSK and AstraZeneca among top companies told to 'cut US prices or else'*'.

At the outset, it is clarified that the said news item does not pertain to GlaxoSmithKline Pharmaceuticals Limited ("the **Company**"). Instead, it concerns GSK plc (previously GlaxoSmithKline plc), our ultimate parent company in the United Kingdom. The Company does not have any further information regarding the events stated in the said article and is therefore unable to comment on any material impact of the same on the Company. The Company is also not aware of any information or announcement, including any pending announcement, which in the Company's opinion, could have a bearing on the share price of the Company. Accordingly, at present, the Company does not have any information concerning the events stated in the said article which is disclosable in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151